GlassScriptPhysician profile
Anil Nachnani
NPI 1679558738
$3,782.43
in general payments reported to CMS, 2019-2025
45 companies · $857 in 2025
The $857 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $52.95 · 2021: $338 · 2022: $810 · 2023: $825 · 2024: $628 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,294 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,293.58 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.13 | 2021-2025 | |
| Novo Nordisk INC | $607.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $246.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $218.46 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $215.62 | 2022-2023 | |
| Astellas Pharma US INC | $197.88 | 2021-2025 | Veozah |
| Amgen INC. | $161.43 | 2019-2025 | Krystexxa |
| Exact Sciences Corporation | $111.34 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $90.23 | 2023-2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $74.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $63.66 | 2019-2024 | Verquvo, Capvaxive, Gardasil 9 |
| Axsome Therapeutics, INC. | $60.87 | 2022-2025 | Sunosi, Auvelity |
| Teva Pharmaceuticals USA, INC. | $58.39 | 2019-2023 | Austedo |
| Lilly USA, LLC | $56.05 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $55.06 | 2021-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Nachnani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.